Stine Sofie Frank Lende

The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection. / Møhlenberg, Michelle; Monrad, Ida; Vibholm, Line K. et al.

I: Journal of Interferon and Cytokine Research, Bind 41, Nr. 11, 11.2021, s. 407-414.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Møhlenberg M, Monrad I, Vibholm LK, Nielsen SSF, Frattari GS, Schleimann MH et al. The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection. Journal of Interferon and Cytokine Research. 2021 nov.;41(11):407-414. doi: 10.1089/jir.2021.0106

Author

Møhlenberg, Michelle ; Monrad, Ida ; Vibholm, Line K. et al. / The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection. I: Journal of Interferon and Cytokine Research. 2021 ; Bind 41, Nr. 11. s. 407-414.

Bibtex

@article{2e288dcfdcf3413bbe936a6e98970f20,
title = "The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection",
abstract = "Genetic polymorphisms at the IFNL4 loci are known to influence the clinical outcome of several different infectious diseases. Best described is the association between the IFNL4 genotype and hepatitis C virus clearance. However, an influence of the IFNL4 genotype on the adaptive immune system was suggested by several studies but never investigated in humans. In this cross-sectional study, we have genotyped 201 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive participants for 3 IFNL4 polymorphisms (rs368234815, rs12979860, and rs117648444) and stratified them according to the IFNλ4 activity. Based on this stratification, we investigated the association between the IFNL4 genotype and the antibody as well as the CD8+ T cell response in the acute phase of the SARS-CoV-2 infection. We observed no differences in the genotype distribution compared with a Danish reference cohort or the 1,000 Genome Project, and we were not able to link the IFNL4 genotype to changes in either the antibody or CD8+ T cell responses of these patients. ",
keywords = "antibody, COVID-19, genetics, Interferon lambda-4, SARS-CoV-2, T cell response",
author = "Michelle M{\o}hlenberg and Ida Monrad and Vibholm, {Line K.} and Nielsen, {Stine S.F.} and Frattari, {Giacomo Schmidt} and Schleimann, {Mariane H{\o}gsbjerg} and Rikke Olesen and Mads Kjolby and Gunst, {Jesper Damsgaard} and S{\o}gaard, {Ole Schmeltz} and O'Brien, {Thomas R.} and Martin Tolstrup and Rune Hartmann",
note = "Funding Information: The funding source had no role in the study design, collection, analysis, and interpretation of data, writing of the article, or the decision to submit the article for publication. This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics. Publisher Copyright: {\textcopyright} Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.",
year = "2021",
month = nov,
doi = "10.1089/jir.2021.0106",
language = "English",
volume = "41",
pages = "407--414",
journal = "Journal of Interferon & Cytokine Research",
issn = "1079-9907",
publisher = "Mary AnnLiebert, Inc. Publishers",
number = "11",

}

RIS

TY - JOUR

T1 - The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection

AU - Møhlenberg, Michelle

AU - Monrad, Ida

AU - Vibholm, Line K.

AU - Nielsen, Stine S.F.

AU - Frattari, Giacomo Schmidt

AU - Schleimann, Mariane Høgsbjerg

AU - Olesen, Rikke

AU - Kjolby, Mads

AU - Gunst, Jesper Damsgaard

AU - Søgaard, Ole Schmeltz

AU - O'Brien, Thomas R.

AU - Tolstrup, Martin

AU - Hartmann, Rune

N1 - Funding Information: The funding source had no role in the study design, collection, analysis, and interpretation of data, writing of the article, or the decision to submit the article for publication. This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics. Publisher Copyright: © Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.

PY - 2021/11

Y1 - 2021/11

N2 - Genetic polymorphisms at the IFNL4 loci are known to influence the clinical outcome of several different infectious diseases. Best described is the association between the IFNL4 genotype and hepatitis C virus clearance. However, an influence of the IFNL4 genotype on the adaptive immune system was suggested by several studies but never investigated in humans. In this cross-sectional study, we have genotyped 201 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive participants for 3 IFNL4 polymorphisms (rs368234815, rs12979860, and rs117648444) and stratified them according to the IFNλ4 activity. Based on this stratification, we investigated the association between the IFNL4 genotype and the antibody as well as the CD8+ T cell response in the acute phase of the SARS-CoV-2 infection. We observed no differences in the genotype distribution compared with a Danish reference cohort or the 1,000 Genome Project, and we were not able to link the IFNL4 genotype to changes in either the antibody or CD8+ T cell responses of these patients.

AB - Genetic polymorphisms at the IFNL4 loci are known to influence the clinical outcome of several different infectious diseases. Best described is the association between the IFNL4 genotype and hepatitis C virus clearance. However, an influence of the IFNL4 genotype on the adaptive immune system was suggested by several studies but never investigated in humans. In this cross-sectional study, we have genotyped 201 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive participants for 3 IFNL4 polymorphisms (rs368234815, rs12979860, and rs117648444) and stratified them according to the IFNλ4 activity. Based on this stratification, we investigated the association between the IFNL4 genotype and the antibody as well as the CD8+ T cell response in the acute phase of the SARS-CoV-2 infection. We observed no differences in the genotype distribution compared with a Danish reference cohort or the 1,000 Genome Project, and we were not able to link the IFNL4 genotype to changes in either the antibody or CD8+ T cell responses of these patients.

KW - antibody

KW - COVID-19

KW - genetics

KW - Interferon lambda-4

KW - SARS-CoV-2

KW - T cell response

UR - http://www.scopus.com/inward/record.url?scp=85119824637&partnerID=8YFLogxK

U2 - 10.1089/jir.2021.0106

DO - 10.1089/jir.2021.0106

M3 - Journal article

C2 - 34788130

AN - SCOPUS:85119824637

VL - 41

SP - 407

EP - 414

JO - Journal of Interferon & Cytokine Research

JF - Journal of Interferon & Cytokine Research

SN - 1079-9907

IS - 11

ER -